ABSTRACT
Short-tandem repeat (STR) expansions are an important class of pathogenic genetic variants. Over forty neurological and neuromuscular diseases are caused by STR expansions, with 37 different genes implicated to date. Here we describe the use of programmable targeted long-read sequencing with Oxford Nanopore’s ReadUntil function for parallel genotyping of all known neuropathogenic STRs in a single, simple assay. Our approach enables accurate, haplotype-resolved assembly and DNA methylation profiling of expanded and non-expanded STR sites. In doing so, the assay correctly diagnoses all individuals in a cohort of patients (n = 27) with various neurogenetic diseases, including Huntington’s disease, fragile X syndrome and cerebellar ataxia (CANVAS) and others. Targeted long-read sequencing solves large and complex STR expansions that confound established molecular tests and short-read sequencing, and identifies non-canonical STR motif conformations and internal sequence interruptions. Even in our relatively small cohort, we observe a wide diversity of STR alleles of known and unknown pathogenicity, suggesting that long-read sequencing will redefine the genetic landscape of STR expansion disorders. Finally, we show how the flexible inclusion of pharmacogenomics (PGx) genes as secondary ReadUntil targets can identify clinically actionable PGx genotypes to further inform patient care, at no extra cost. Our study addresses the need for improved techniques for genetic diagnosis of STR expansion disorders and illustrates the broad utility of programmable long-read sequencing for clinical genomics.
One sentence summary This study describes the development and validation of a programmable targeted nanopore sequencing assay for parallel genetic diagnosis of all known pathogenic short-tandem repeats (STRs) in a single, simple test.
Competing Interest Statement
I.W.D. manages a fee-for-service sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies but has no further financial relationship. H.G. & J.M.F. have received travel and accommodation expenses to speak at Oxford Nanopore Technologies conferences. The authors declare no other competing financial or non-financial interests.
Funding Statement
We acknowledge the following funding support: Australian Medical Research Futures Fund (MRFF) Investigator Grant MRF1173594 (to I.W.D.); Australian National Health and Medical Research Council (NHMRC) Fellowship APP1122952 (to G.R.); MRFF Genomics Future Health Missions Grant 2007681 (to N.G.L.); Australian Government Research Training Program (RTP) Scholarship (to C.S.); Philanthropic support from The Kinghorn Foundation (to I.W.D.); Margaret and Terry Orr Memorial Fund (to N.G.L.); Paul Ainsworth Family Foundation (to K.R.K.); Working Group Co-Lead Award from the Michael J. Fox Foundation, Aligning Science Across Parkinson's (ASAP) initiative (to K.R.K.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients consulting at neurology clinics in New South Wales (NSW) were consented for genomic analysis by nanopore sequencing under St Vincent's Hospital Human Research Ethics Committee protocol 2019/ETH12538. Patients in Western Australia (WA) were consented under Human Research Ethics Committee of the University of Western Australia protocol 2019/RA/4/20/1008. Approval was granted in both cases.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All software used in this study is free and open source, with the exception of the proprietary ONT base-calling software Guppy. Where permitted under patient ethics protocols, sequencing data from this study has been uploaded to the NCBI Sequence Read Archive (SRA) and will be open for public access at the time of publication.
